Bayer’s Rally Has a Fresh Narrative, But the Chart Sends a Warning
Published on 07/04/2026 at 13:56 | Redaktion boerse-global.de
Bayer’s shares have surged more than 50% in a month, propelled by a landmark US Supreme Court ruling and an aggressive new trade petition against Chinese glyphosate imports. But with the stock trading near its 52-week high and its 14-day relative strength index at 85.1 – deep in overbought territory – the question is no longer whether the narrative has changed, but whether the price already reflects it.
Behind the move lies a concerted restructuring effort. The company has bundled its US glyphosate business into a newly created subsidiary, Ruveon LLC, a step analysts see as a potential precursor to a full spin-off or sale. Deutsche Bank upgraded the stock to “Buy” with a €60 target, arguing that the question is now “not if, but when and how” Bayer will break apart its portfolio. On the Xetra exchange, the shares jumped 8.9% on the day of the court decision, closing at €53.04 on Friday – just 1.5% below the fresh 52-week high of €53.86 set on July 3. Year-to-date, the stock has gained 39.5%.
The Supreme Court’s 7-2 ruling on June 25 effectively blocks state-level failure-to-warn claims against Monsanto, the legal foundation for roughly 200,000 pending lawsuits. That decision overturned a $1.25 million verdict and came after Bayer had already spent more than $10 billion in legal costs over nearly a decade. Yet the victory does not close the roundup chapter entirely; other legal strands remain active, and a final settlement hearing is set for August 19.
Should investors sell immediately? Or is it worth buying Bayer?
What complicates the picture is the company’s simultaneous offensive on a second front. On June 30, Bayer, through Monsanto and Ruveon, filed an antidumping and countervailing duty petition with the US Commerce Department and the International Trade Commission, seeking tariffs on Chinese glyphosate. The company frames itself as the last domestic producer squeezed by cheap imports. The petition has already drawn fire from farm groups that supported Bayer in the Supreme Court fight, and approval is far from guaranteed. If the petition fails, Bayer’s glyphosate business will continue to face structural pricing pressure. Management itself has guided for a 2% to 6% decline in glyphosate sales for 2026, citing generic Chinese material trading below historical medians.
Technicians point to additional caution signals. The stock now sits 36.5% above its 50-day moving average of €38.86, an extreme gap that often precedes a pullback. Annualized 30-day volatility stands at 63.2%, reflecting a jittery market. A corrective move could test that moving average as support.
The next catalysts are clearly marked on the calendar. Bayer reports second-quarter earnings on August 4 – the first chance to see how the Ruveon restructuring affects the financials. Then on August 19, a US court will decide on final approval of the multibillion-dollar settlement. Meanwhile, investors will watch for any signal from the Commerce Department or ITC on whether they will open an antidumping investigation; no timeline has been set.
For now, the combination of legal relief, structural separation, and a trade-policy gamble has driven one of the strongest re-ratings in Bayer’s recent history. Whether that momentum holds depends on execution in the courtroom, the trade commission, and the quarterly report – and on whether the market is willing to look past a dangerously overbought chart.
Ad
Bayer Stock: New Analysis - 4 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
